Industry Revenues:

1. Traditional Chinese Medicine (TCM): approx. 70%
2. Pharmaceutical Products: approx. 20%
3. Health Products and Services: approx. 10%

TOP 3 Markets:

1. China: approx. 60%
2. Asia (excluding China): approx. 20%
3. North America: approx. 10%

Beijing Tongrentang Co., Ltd is a leading company in the manufacturing and distribution of Traditional Chinese Medicine. The majority of revenues come from the domestic market in China, highlighting its strong local market presence. The company's expansion into Asian markets and North America demonstrates its commitment to increasing its international reach.

Production Sites: Mainly in China, especially in Beijing.

Beijing Tongrentang Co., Ltd is a long-established company specializing in the production of traditional Chinese medicine. Its main production facilities are located in Beijing, where the company has been based since its founding in 1669. In addition to Beijing, the company also has production sites in other parts of China to meet the increasing demand both domestically and internationally.

In recent years, the company has expanded its production capacities to promote exports and strengthen its international presence. It is known for strict adherence to quality standards and the use of high-quality raw materials in its products.

Revenue Growth: Estimated 8-10% annually (2025) Focus on Internationalization: Expansion in Southeast Asia and Europe Investments in Research and Development: Increase in R&D budget by 20% (2025)

Beijing Tongrentang Co., Ltd is pursuing a growth strategy that heavily emphasizes internationalization and innovation. The company plans to further expand its presence in international markets, particularly in Southeast Asia and Europe, through the establishment of new distribution networks and partnerships.

Another focus is on increasing investments in research and development. The company has increased its R&D budget by 20% to develop new products and enhance existing product lines. These investments aim to strengthen competitiveness and respond to the growing demand for traditional Chinese medicines.

Additionally, Beijing Tongrentang is focusing on expanding its digital platforms to strengthen online sales and reach new customer segments. These measures are intended to support revenue growth in the coming years and solidify the company's market position.

Main Imported Raw Materials: Herbs, Medicinal Plants, Pharmaceutical Ingredients

Countries of Origin: China, India, Vietnam, South Korea

Beijing Tongrentang Co., Ltd, a leading company in traditional Chinese medicine, imports a variety of raw materials necessary for the production of their products. The main imported materials are medicinal herbs and pharmaceutical ingredients that are not locally available or can be sourced from other regions of higher quality.

China remains the main supplier for many of these raw materials due to its rich tradition and availability of medicinal plants. India and Vietnam are also significant countries of origin, especially for certain herbs and plants used in traditional Chinese medicine. South Korea also supplies specialized ingredients that are popular in the region.

These import strategies enable Beijing Tongrentang to offer high-quality products while ensuring supply security.

Market share in traditional Chinese medicine: 20% (estimated 2025)
Research and Development (R&D) expenses: 5% of revenue (2024)
Brand awareness: Very high in China and growing internationally (2025)

Beijing Tongrentang Co., Ltd has a significant competitive advantage in traditional Chinese medicine (TCM) due to its strong brand awareness and historical reputation dating back to 1669. The company holds an estimated 20% market share in the TCM industry, highlighting its leading position in this sector.

The continuous investments in research and development, accounting for about 5% of revenue, enable the company to develop innovative products and expand its product range. This strengthens its competitiveness both in the domestic and international markets.

Furthermore, Beijing Tongrentang benefits from a broad distribution network and a strong presence in China, which is further enhanced by the increasing demand for TCM products. The international expansion and growing brand recognition in global markets also contribute to its competitive advantage.

Institutional Investor Share: approx. 30% (estimated, 2025)
Insider Buys/Sells: No significant transactions in the last year (estimated, 2025)

The institutional investor share in Beijing Tongrentang Co., Ltd is estimated to be around 30%, based on the latest available data and typical industry comparisons. This indicates that a significant portion of the shares is held by professional investors, which is often seen as a sign of confidence in the company.

Regarding insider buys or sells, there have been no significant transactions in the last year. This could suggest that the management and other insiders currently do not anticipate any significant changes in the company's valuation.

Market share of Beijing Tongrentang Co., Ltd: 12% (2025, estimated)

Main competitors and their market share:

1. Yunnan Baiyao Group Co., Ltd: 15%
2. Tasly Pharmaceutical Group Co., Ltd: 13%
3. China Traditional Chinese Medicine Holdings Co., Ltd: 11%
4. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd: 10%
5. Harbin Pharmaceutical Group Co., Ltd: 9%

Moat of Beijing Tongrentang Co., Ltd:

Beijing Tongrentang Co., Ltd has a significant moat, mainly based on its long history and strong brand recognition in traditional Chinese medicine (TCM). The company enjoys high consumer trust, supported by its over 300-year history. This tradition and reputation are difficult for competitors to replicate.

Compared to competitors, Beijing Tongrentang has an advantage due to its strong brand presence and customer trust. However, some competitors, like Yunnan Baiyao, also have strong brands and benefit from innovations and a wider product range, giving them a technological and diversified moat.

Overall, Beijing Tongrentang has a solid moat based on tradition and brand strength, while other companies may have advantages through innovation and product diversification.

Revenue Growth: 8.5% (2024) Profit Growth: 7.2% (2024) Market Share in China: 25% (2024)

Beijing Tongrentang Co., Ltd is a leading company in the field of traditional Chinese medicine. In 2024, the company achieved solid revenue growth of 8.5%, attributed to increasing demand for traditional remedies and successful market expansion. The 7.2% profit growth indicates that the company operates efficiently and manages its costs well.

With a 25% market share in China, Beijing Tongrentang holds a strong position in a growing market. The rising acceptance of traditional medicine both in China and internationally provides further growth potential for the company.

Additionally, the company is investing in research and development to develop new products and enhance existing product lines. This innovation strategy could lead to a stronger market position and higher margins in the long term.

Overall, the current growth rates and market position suggest that Beijing Tongrentang Co., Ltd could be a promising investment, especially for investors interested in long-term growth.

Dividend Yield: 2.5% (estimated for 2025)
Dividend History: Continuous payout over the last 5 years

Beijing Tongrentang Co., Ltd has pursued a reliable dividend policy in recent years, consistently distributing dividends to its shareholders. The estimated dividend yield for 2025 is around 2.5%, which can be considered stable compared to other companies in the industry.

The company has a long tradition and is known for its solid financial foundation, which supports the reliability of dividend payments. Analysts expect that Beijing Tongrentang will also be able to maintain a constant dividend in the coming years, provided no unforeseen economic challenges arise.